Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 2Phase 2 1

Status

Recruiting 4Completed 2

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6Sarcoma 1Gynecologic 1CNS 1

Conditions

Breast Neoplasms 5Neoplasms by Site 1Neoplasms 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Breast Diseases 1Brain Neoplasms 1Brain Diseases 1Advanced Breast Cancer 1

Interventions

Paclitaxel 162Fulvestrant 157Trastuzumab 156pembrolizumab 146Letrozole 137Carboplatin 118pertuzumab 104Capecitabine 104Specimen Handling 102Cyclophosphamide 102Anastrozole 90palbociclib 86abemaciclib 82Magnetic Resonance Spectroscopy 81exemestane 76Docetaxel 76Tamoxifen 75ribociclib 74trastuzumab deruxtecan 68Radiotherapy 62Biopsy 59Surveys and Questionnaires 55Gemcitabine 53130-nm albumin-bound paclitaxel 53olaparib 52sacituzumab govitecan 51Blood Specimen Collection 51Standard of Care 49Taxes 48eribulin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
RAD1901 × Breast × 1 year × Clear all
NCT05386108 2026-06-04

ELECTRA

Stemline Therapeutics, Inc.

Phase 1/2 Recruiting
73 enrolled
BreastCNS

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT07198724 2026-04-09

ERADICATE

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
65 enrolled
Breast

Breast Neoplasms

NCT06382948 2026-04-03

ADELA

MedSIR

Phase 3 Recruiting
240 enrolled
Breast

Advanced Breast Cancer

NCT05963997 2026-03-23

SUMIT-ELA

Carrick Therapeutics Limited

Phase 1/2 Completed
49 enrolled
Breast

Breast Neoplasms

NCT07222215 2026-01-22

CAPELA

Dana-Farber Cancer Institute

Phase 2 Recruiting
297 enrolled
Breast

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed
478 enrolled 16 charts 1 FDA
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡